Product Description
Erlocip 150 Tablet is an anti-cancer medication. Epidermal growth factor receptors (EGFR) are expressed on the lung cancer cell surfaces that modulate their growth. This medicine works by binding the chemical messenger, EGFR, hence, inhibits the cancer signaling pathways mediated by EGFR.Targeted Cancer TherapyErlocip 150 offers advanced, targeted treatment for patients diagnosed with non-small cell lung cancer (NSCLC) and pancreatic cancer. Its active ingredient, Erlotinib Hydrochloride, works as a tyrosine kinase inhibitor, selectively interfering with enzymes implicated in the proliferation of cancer cells. This precision medicine approach aims to inhibit tumor progression while minimizing effects on healthy tissues.
Strict Prescription RequirementDue to its potent activity and targeted use, Erlocip 150 should only be obtained and consumed under a certified oncologist's prescription. This ensures appropriate dosages, thorough monitoring, and maximized therapeutic benefit. Always follow your healthcare provider's instructions and consult them regarding any concerns or adverse effects during therapy.
Optimal Storage & Shelf LifeTo maintain Erlocip 150's effectiveness, it should be stored below 30C in a dry place, shielded from direct sunlight. Each tablet retains its stability and therapeutic quality for up to 24 months from manufacture, as indicated on the packaging. Check the expiration date before use and keep the medication out of reach of children.
FAQ's of 150mg Erlocip:
Q: How should Erlocip 150 be administered for best results?
A: Erlocip 150 is an oral medication and should be taken exactly as prescribed by your oncologist, usually once daily on an empty stomach or as directed. Swallow the tablet whole with water and avoid cutting or crushing it unless instructed otherwise.
Q: What are the primary indications for Erlocip 150?
A: Erlocip 150 is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Its use must be supervised by an oncologist who will determine suitable patient eligibility based on clinical evaluation.
Q: When should I start or stop taking Erlocip 150?
A: You should begin Erlocip 150 therapy as soon as prescribed by your oncologist and continue taking it until your doctor advises you to stop. Do not discontinue or adjust the dose without consulting your healthcare provider, even if you feel better or experience side effects.
Q: Where can I purchase Erlocip 150 tablets?
A: Erlocip 150 is available only through authorized pharmacies and distributors in India, strictly against a valid oncologist's prescription. It is not available as an over-the-counter medication.
Q: What is the process for obtaining Erlocip 150 in India?
A: To obtain Erlocip 150, you must present a prescription from a qualified oncologist at a licensed pharmacy. The pharmacist will provide the medication along with a product leaflet containing detailed usage instructions.
Q: What are the benefits of taking Erlocip 150 as a cancer therapy?
A: Erlocip 150 aims to inhibit tumor cell growth by blocking specific enzymes (tyrosine kinases) involved in cancer cell proliferation. This targeted action helps slow disease progression and may improve overall outcomes in NSCLC and pancreatic cancer when administered correctly.
Q: Are there specific storage and safety instructions for Erlocip 150?
A: Yes, Erlocip 150 should be stored below 30C in a dry environment, protected from light, and out of children's reach. Ensure the tablets remain in their original blister packaging until use to maintain stability and efficacy.